Biocon Q4 FY26: Revenue Holds Steady Amid Rising Cost Pressures Impacting Margins

📊 Financial Snapshot ✅ Net Profit at ₹126 Cr, down sharply by nearly 63% YoY from ₹340 Cr ✅ Revenue edges up 2% YoY to ₹4,520 Cr, showing steady topline momentum ✅ EBITDA slips 6% YoY to ₹1,020 Cr, reflecting margin pressures 📈 Margin & Efficiency Trends ⚡ EBITDA Margin contracts to 22.6% from 24.4% YoY, highlighting cost challenges ⚡ Net Profit Margin drops steeply to 2.8% from 7.7%, signaling profitability stress ⚡ Operating Margin also down, confirming rising expense impact 🔍 What This Means 🧪 Revenue growth indicates resilience in Biocon’s core pharma and biotech operations despite a tough global pricing environment 🧪 Profitability took a hit due to higher input costs and margin compression, a common theme in generics and biosimilars sectors 🧪 Stable debt-to-equity ratio offers some balance, but sustained margin pressure could test financial flexibility 📌 Sector Insight 🏭 Indian pharma players like Biocon face intense pricing pressures internationally, especially in biosimilars, making margin management critical